Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression

Stefania Tommasi, Brunella Pilato, Claudia Carella, Antonia Lasorella, Katia Danza, Ivan Vallini, Simona De Summa, Emanuele Naglieri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Castration resistant prostate cancer (CRPC) represents the most aggressive status of this neoplastic disease, also characterized by the absence of biomarkers predictive of clinical outcome. New drugs as abiraterone or enzalutamide, affecting androgen receptor pathway at different levels, inhibit the proliferative advantage of prostate cancer cells with important long term benefits. Despite the advantages of this second-generation androgen deprivation therapy (ADT), resistance mechanisms, primitive or acquired, often develop. The existence of androgen receptor (AR) splice variants (AR-Vs), in particular AR-V7 expression detected in circulating tumor cells (CTCs), represents an example of acquired resistance, as evidenced in preclinical and clinical studies. Recent studies also have suggested the role of AR-V7 as a prognostic biomarker in mCRPC. In this field, hot topics are the methodology used to isolate CTC and the assay for AR-V7 measurement. Our study aims to develop a standardized operating procedure (SOP) to evaluate AR-V7 in CRPC. Method: The application of a realized cell based Reference Sample as Standardized Quality Control tool for CTC-AR-V7 assay has been shown. Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer. Results and Conclusions: The standardized procedure has high sensitivity and specificity and enables the detection and quantification of the spliced variant with respect to the full length AR (AR-FL) mRNA in CTC DNA purified from the blood of patients with CRPC. This procedure has been further validated in a consecutive series of patients with mCRPC, confirming its role as prognostic biomarker.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
JournalProstate
Volume79
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Circulating Neoplastic Cells
Castration
Androgen Receptors
Prostatic Neoplasms
Polymerase Chain Reaction
Biomarkers
Quality Control
Androgens

Keywords

  • androgen receptor
  • AR-V7 splicing variant
  • castration resistant
  • metastatic prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. / Tommasi, Stefania; Pilato, Brunella; Carella, Claudia; Lasorella, Antonia; Danza, Katia; Vallini, Ivan; De Summa, Simona; Naglieri, Emanuele.

In: Prostate, Vol. 79, No. 1, 01.01.2019, p. 54-61.

Research output: Contribution to journalArticle

Tommasi, Stefania ; Pilato, Brunella ; Carella, Claudia ; Lasorella, Antonia ; Danza, Katia ; Vallini, Ivan ; De Summa, Simona ; Naglieri, Emanuele. / Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. In: Prostate. 2019 ; Vol. 79, No. 1. pp. 54-61.
@article{5dfd516c9a7247608fcaad784dff256b,
title = "Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression",
abstract = "Background: Castration resistant prostate cancer (CRPC) represents the most aggressive status of this neoplastic disease, also characterized by the absence of biomarkers predictive of clinical outcome. New drugs as abiraterone or enzalutamide, affecting androgen receptor pathway at different levels, inhibit the proliferative advantage of prostate cancer cells with important long term benefits. Despite the advantages of this second-generation androgen deprivation therapy (ADT), resistance mechanisms, primitive or acquired, often develop. The existence of androgen receptor (AR) splice variants (AR-Vs), in particular AR-V7 expression detected in circulating tumor cells (CTCs), represents an example of acquired resistance, as evidenced in preclinical and clinical studies. Recent studies also have suggested the role of AR-V7 as a prognostic biomarker in mCRPC. In this field, hot topics are the methodology used to isolate CTC and the assay for AR-V7 measurement. Our study aims to develop a standardized operating procedure (SOP) to evaluate AR-V7 in CRPC. Method: The application of a realized cell based Reference Sample as Standardized Quality Control tool for CTC-AR-V7 assay has been shown. Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer. Results and Conclusions: The standardized procedure has high sensitivity and specificity and enables the detection and quantification of the spliced variant with respect to the full length AR (AR-FL) mRNA in CTC DNA purified from the blood of patients with CRPC. This procedure has been further validated in a consecutive series of patients with mCRPC, confirming its role as prognostic biomarker.",
keywords = "androgen receptor, AR-V7 splicing variant, castration resistant, metastatic prostate cancer",
author = "Stefania Tommasi and Brunella Pilato and Claudia Carella and Antonia Lasorella and Katia Danza and Ivan Vallini and {De Summa}, Simona and Emanuele Naglieri",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pros.23710",
language = "English",
volume = "79",
pages = "54--61",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression

AU - Tommasi, Stefania

AU - Pilato, Brunella

AU - Carella, Claudia

AU - Lasorella, Antonia

AU - Danza, Katia

AU - Vallini, Ivan

AU - De Summa, Simona

AU - Naglieri, Emanuele

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Castration resistant prostate cancer (CRPC) represents the most aggressive status of this neoplastic disease, also characterized by the absence of biomarkers predictive of clinical outcome. New drugs as abiraterone or enzalutamide, affecting androgen receptor pathway at different levels, inhibit the proliferative advantage of prostate cancer cells with important long term benefits. Despite the advantages of this second-generation androgen deprivation therapy (ADT), resistance mechanisms, primitive or acquired, often develop. The existence of androgen receptor (AR) splice variants (AR-Vs), in particular AR-V7 expression detected in circulating tumor cells (CTCs), represents an example of acquired resistance, as evidenced in preclinical and clinical studies. Recent studies also have suggested the role of AR-V7 as a prognostic biomarker in mCRPC. In this field, hot topics are the methodology used to isolate CTC and the assay for AR-V7 measurement. Our study aims to develop a standardized operating procedure (SOP) to evaluate AR-V7 in CRPC. Method: The application of a realized cell based Reference Sample as Standardized Quality Control tool for CTC-AR-V7 assay has been shown. Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer. Results and Conclusions: The standardized procedure has high sensitivity and specificity and enables the detection and quantification of the spliced variant with respect to the full length AR (AR-FL) mRNA in CTC DNA purified from the blood of patients with CRPC. This procedure has been further validated in a consecutive series of patients with mCRPC, confirming its role as prognostic biomarker.

AB - Background: Castration resistant prostate cancer (CRPC) represents the most aggressive status of this neoplastic disease, also characterized by the absence of biomarkers predictive of clinical outcome. New drugs as abiraterone or enzalutamide, affecting androgen receptor pathway at different levels, inhibit the proliferative advantage of prostate cancer cells with important long term benefits. Despite the advantages of this second-generation androgen deprivation therapy (ADT), resistance mechanisms, primitive or acquired, often develop. The existence of androgen receptor (AR) splice variants (AR-Vs), in particular AR-V7 expression detected in circulating tumor cells (CTCs), represents an example of acquired resistance, as evidenced in preclinical and clinical studies. Recent studies also have suggested the role of AR-V7 as a prognostic biomarker in mCRPC. In this field, hot topics are the methodology used to isolate CTC and the assay for AR-V7 measurement. Our study aims to develop a standardized operating procedure (SOP) to evaluate AR-V7 in CRPC. Method: The application of a realized cell based Reference Sample as Standardized Quality Control tool for CTC-AR-V7 assay has been shown. Then the development, the performance evaluation and contextualization in a clinical setting of this standardized operating procedure (SOP) have been reported to evaluate the prognostic biomarker AR-V7 in metastatic prostate cancer. Results and Conclusions: The standardized procedure has high sensitivity and specificity and enables the detection and quantification of the spliced variant with respect to the full length AR (AR-FL) mRNA in CTC DNA purified from the blood of patients with CRPC. This procedure has been further validated in a consecutive series of patients with mCRPC, confirming its role as prognostic biomarker.

KW - androgen receptor

KW - AR-V7 splicing variant

KW - castration resistant

KW - metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85052369117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052369117&partnerID=8YFLogxK

U2 - 10.1002/pros.23710

DO - 10.1002/pros.23710

M3 - Article

VL - 79

SP - 54

EP - 61

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -